Expert Review of Clinical Pharmacology

Papers
(The H4-Index of Expert Review of Clinical Pharmacology is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock186
Safety assessment of propranolol for infantile hemangioma: a study in an Asian population165
Dasiglucagon for treating severe hypoglycemia in patients with diabetes53
The continuum of care of anticancer treatment-induced hypothyroidism in patients with solid non-thyroid tumors: time for an intimate collaboration between oncologists and endocrinologists42
Regional variation in longitudinal trajectories of primary care opioids prescribing across Health Boards in Scotland: a population-based study42
Effectiveness and safety of thiopurines in inflammatory bowel disease patients with NUDT15 polymorphism: a real-world retrospective study40
Tocilizumab for the treatment of non‐critical COVID‐19 pneumonia: an overview of the rationale and clinical evidence to date39
Clinical pharmacology of antiplatelet drugs39
Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights35
Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome33
Telmisartan (and/or nitrosamine) - induced occult melanoma: first reported case in world literature29
Comparison of the relative efficacy of different biologics in different body areas in patients with moderate to severe psoriasis receiving biologics and tofacitinib in phase 3 randomized controlled tr29
Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials29
Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments27
Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis27
The use of oral GnRH antagonists to inhibit the LH surge in women undergoing ovarian stimulation for in vitro fertilization27
Sodium-glucose co-transporter 2 inhibition and acute myocardial infarction: the DAPA-MI and EMPACT-MI trials26
Immune checkpoint inhibition of metastatic melanoma: achieving high efficacy in the face of high toxicity26
Reliance is key to effective access and oversight of medical products in case of public health emergencies25
Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis24
The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers23
Antimicrobial safety considerations in critically ill patients: part I: focused on acute kidney injury22
0.088088035583496